Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Weight-Loss Drug Wars: Novo Nordisk Eyes Vials for Wegovy in High-Stakes Battle

GLP-1 Medications: Separating Hype from Health with Expert Insights

Novo Nordisk Doubles Down: Lawsuit Against Hims & Hers Continues Despite 'Wegovy Pill' Plans Scrapped

Weight-Loss Drug Wars Escalate: Novo Nordisk Sues Hims & Hers Over Compounded Semaglutide

The Weight-Loss Revolution: Telehealth Giant Hims & Hers Dives into the GLP-1 Market

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

Novo Nordisk CEO Projects Strong Supply for Game-Changing Wegovy Pill

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

Uncovering Europe's Next Big Movers: 5 Stocks Riding a Bullish Wave

The Shifting Sands of US Drug Pricing: Why Big Pharma Investors are on Edge

A New Era in Obesity Treatment: The Rise of Oral Weight-Loss Solutions

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

European Markets Tread Water: Cautious Optimism Brews Ahead of Earnings Season

The Oral Revolution: Novo Nordisk's GLP-1 Pill Changes the Game

Kicking Off the Year: Unpacking the 'Final Trades' for 2026

Novo Nordisk's Bold Gambit: Wegovy Price Slashed by Half for China Debut

The Last-Minute Playbook: Unpacking 2025's Final Market Calls

A Landmark Win for Innovation: Delhi High Court Upholds Novo Nordisk's Semaglutide Patent

The Delhi High Court's Landmark Ruling on Semaglutide: A Win for Accessibility

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

The Unforeseen Hope: Ozempic's Astonishing Link to Alzheimer's

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

The Frustrating Wait: Why Wegovy Remains a Distant Dream for Many Canadians

Major Win: Delhi High Court Greenlights Dr. Reddy's for Export-Only Weight-Loss Drug Production

The Enduring Quest: Semaglutide and the Unyielding Challenge of Alzheimer's

Eli Lilly's Zepbound Gets a Significant Price Drop: What It Means for Patients and the Market

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

Europe's Quiet Ascent: How Old-World Giants Are Reshaping Global Stock Leadership

A New Era for Weight Loss: The Revolution of GLP-1 Pills and Monthly Shots

A Glimmer of Hope: Repurposing Drugs in the Fight Against Alzheimer's

Novo Nordisk's Alzheimer's Trial: A Minor Blip for a Pharma Giant

Amycretin: Is Novo Nordisk's Oral Wonder Drug the Future of Weight Loss and Diabetes Treatment?

A Glimmer of Hope: Novo Nordisk's Next-Gen Drug Shows Remarkable Promise in Battling Obesity and Diabetes

The Closing Bell: Navigating Today's Final Trades with BABA, ZM, NVO, and TJX

Novo Nordisk's Alzheimer's Trial Setback: A Closer Look

A Glitch in the Hope: Ozempic's Oral Sibling Fails to Deliver in Alzheimer's Trials

Novo Nordisk's Alzheimer's Ambition Dashed: Semaglutide Trial Fails, Stock Plummets

The Trillion-Dollar Bet: How Eli Lilly is Reshaping the Global Economy